[go: up one dir, main page]

ATE507209T1 - Referenzstandard zur charakterisierung von rosuvastatin - Google Patents

Referenzstandard zur charakterisierung von rosuvastatin

Info

Publication number
ATE507209T1
ATE507209T1 AT04812772T AT04812772T ATE507209T1 AT E507209 T1 ATE507209 T1 AT E507209T1 AT 04812772 T AT04812772 T AT 04812772T AT 04812772 T AT04812772 T AT 04812772T AT E507209 T1 ATE507209 T1 AT E507209T1
Authority
AT
Austria
Prior art keywords
rosuvastatin
characterization
reference standard
standard
analysis
Prior art date
Application number
AT04812772T
Other languages
English (en)
Inventor
Nina Finkelstein
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34676616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE507209(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE507209T1 publication Critical patent/ATE507209T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT04812772T 2003-12-02 2004-12-02 Referenzstandard zur charakterisierung von rosuvastatin ATE507209T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52644903P 2003-12-02 2003-12-02
PCT/US2004/040329 WO2005056534A1 (en) 2003-12-02 2004-12-02 Reference standard for characterization of rosuvastatin

Publications (1)

Publication Number Publication Date
ATE507209T1 true ATE507209T1 (de) 2011-05-15

Family

ID=34676616

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04812772T ATE507209T1 (de) 2003-12-02 2004-12-02 Referenzstandard zur charakterisierung von rosuvastatin

Country Status (13)

Country Link
US (6) US7244844B2 (de)
EP (1) EP1689723B1 (de)
JP (1) JP4733047B2 (de)
KR (1) KR100887264B1 (de)
CN (1) CN1894221B (de)
AT (1) ATE507209T1 (de)
CA (1) CA2546894C (de)
DE (1) DE602004032465D1 (de)
ES (1) ES2364143T3 (de)
IL (1) IL175511A (de)
PT (1) PT1689723E (de)
TW (1) TWI351958B (de)
WO (1) WO2005056534A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
JP4733047B2 (ja) * 2003-12-02 2011-07-27 テバ ファーマシューティカル インダストリーズ リミティド ロスバスタチンの特性評価のためのリファレンス・スタンダード
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
EP1851206B1 (de) 2005-02-22 2012-08-15 Teva Pharmaceutical Industries, Ltd. Rosuvastatin und seine salze die frei von rosuvastatin-alkylether sind und ein verfahren zu ihrer herstellung
EP1968593B1 (de) * 2005-12-20 2017-08-23 LEK Pharmaceuticals d.d. Pharmazeutische zusammensetzung enthaltend (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-ensäure
EP2121631A2 (de) * 2007-03-13 2009-11-25 Teva Pharmaceutical Industries Ltd. Triolform von rosuvastatin
EP2189456A1 (de) * 2008-11-14 2010-05-26 LEK Pharmaceuticals d.d. Neue Omeprazol-Verbindungen
JP5739820B2 (ja) 2008-12-30 2015-06-24 アークル インコーポレイテッド 置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミン化合物
CN103454352B (zh) * 2013-07-30 2015-07-15 广东先强药业有限公司 一种hplc法测定瑞舒伐他汀钙的含量及其有关物质的方法
CN103776939A (zh) * 2014-02-11 2014-05-07 润泽制药(苏州)有限公司 瑞舒伐他汀钙制剂有关物质的制备检测方法
CN108398501A (zh) * 2018-03-02 2018-08-14 海南通用三洋药业有限公司 一种检测瑞舒伐他汀钙有关物质的方法
CN109020902B (zh) * 2018-07-23 2020-06-02 唯智医药科技（北京）有限公司 一种瑞舒伐他汀钙杂质及其制备方法与用途
CN114280181B (zh) * 2021-12-23 2024-06-18 浙江海翔川南药业有限公司 一种瑞舒伐他汀中间体及其有关物质的检测方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37314A (en) * 1863-01-06 Improved composition for lemonade
US633198A (en) * 1899-02-08 1899-09-19 Wilhelm Magnus Hoekerstedt Automatic-lighting torch.
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
EP0554455B1 (de) * 1991-06-19 1997-12-17 Shionogi Seiyaku Kabushiki Kaisha Optisch aktives zwischenprodukt und dessen herstellung
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9626746D0 (en) 1996-12-23 1997-02-12 Knoll Ag Process
GB9812413D0 (en) * 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
SI20070A (sl) 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
HUP0500616A3 (en) 2001-08-16 2011-07-28 Teva Pharma Processes for preparing calcium salt forms of statins
SE0103509D0 (sv) 2001-10-19 2001-10-19 Astrazeneca Ab Rosuvastatin in pre demented states
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
AR039836A1 (es) * 2002-05-21 2005-03-02 Ranbaxy Lab Ltd Proceso para la preparacion de un aldehido de pirimidina util para la preparacion de rosuvastatina
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
AU2002348881A1 (en) 2002-12-10 2004-06-30 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
AU2003269478A1 (en) 2003-08-27 2005-03-16 Hetero Drugs Limited A novel process for amorphous rosuvastatin calcium
WO2005040134A1 (en) * 2003-10-22 2005-05-06 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
CA2546701C (en) * 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
JP4733047B2 (ja) * 2003-12-02 2011-07-27 テバ ファーマシューティカル インダストリーズ リミティド ロスバスタチンの特性評価のためのリファレンス・スタンダード
WO2006035277A2 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
WO2006079611A1 (en) 2005-01-31 2006-08-03 Ciba Specialty Chemicals Holding Inc. Crystalline forms of rosuvastatin calcium salt
US20090124803A1 (en) 2005-03-22 2009-05-14 Pandurang Balwant Deshpande Process for preparation of rosuvastatin
US20080161560A1 (en) 2005-04-04 2008-07-03 Pandurang Balwant Deshpande Process for Preparation of Calcium Salt of Rosuvastatin
JP5416403B2 (ja) 2005-06-24 2014-02-12 レツク・フアーマシユーテイカルズ・デー・デー 純粋な非結晶ロスバスタチンカルシウムの調製方法
EP1912952B1 (de) 2005-06-24 2014-10-15 LEK Pharmaceuticals d.d. Verfahren zur herstellung von amorphem rosuvastatin-calcium frei von verunreinigungen
GB0514078D0 (en) 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process

Also Published As

Publication number Publication date
US7692010B2 (en) 2010-04-06
JP4733047B2 (ja) 2011-07-27
US7741482B2 (en) 2010-06-22
US20070249831A1 (en) 2007-10-25
CA2546894A1 (en) 2005-06-23
TWI351958B (en) 2011-11-11
ES2364143T3 (es) 2011-08-25
CA2546894C (en) 2009-09-08
US8487097B2 (en) 2013-07-16
US7692008B2 (en) 2010-04-06
IL175511A (en) 2011-11-30
IL175511A0 (en) 2006-09-05
US7244844B2 (en) 2007-07-17
TW200522959A (en) 2005-07-16
WO2005056534A1 (en) 2005-06-23
US20070249830A1 (en) 2007-10-25
US20070255059A1 (en) 2007-11-01
KR100887264B1 (ko) 2009-03-06
US20050187234A1 (en) 2005-08-25
JP2007512354A (ja) 2007-05-17
EP1689723A1 (de) 2006-08-16
KR20060098396A (ko) 2006-09-18
EP1689723B1 (de) 2011-04-27
CN1894221A (zh) 2007-01-10
CN1894221B (zh) 2012-08-08
DE602004032465D1 (de) 2011-06-09
US20070244321A1 (en) 2007-10-18
PT1689723E (pt) 2011-07-06
US20090188305A1 (en) 2009-07-30
US7692009B2 (en) 2010-04-06

Similar Documents

Publication Publication Date Title
IL175511A0 (en) Reference standard for characterization of rosuvastatin
ATE269295T1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
ATE307618T1 (de) Vorrichtung zur abgabe von flüchtigen stoffen
ATE335722T1 (de) Benzoylsulfonamide und sulfonylbenzamidine zur verwendung als antitumor-mittel
DE60007095T2 (de) Calanolide zur hemmung von btk
ATE485366T1 (de) Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau
FI20030609L (fi) Analyysi- ja kasvatuslaitteisto
DE60301922D1 (de) Vorrichtung zur Entnahme von Objekten
DE50207852D1 (de) Verwendung von fettalkoholethoxylaten als penetrationsförderer
DE602004025507D1 (de) Vanillin-polymere zwecks verwendung zur verdunklung der haut
DE60318831D1 (de) System zur abgabe von anästhetika
EA200500064A1 (ru) Многофункциональные маркеры продуктов и способы их получения и применения
DE60223780D1 (de) Verfahren zur Entfernung von Kunstrasenböden, entsprechende Verwendung und Produkt
ECSP045466A (es) Inhibidores de la peptido-desformilasa
UY27192A1 (es) Inhibidores de peptido-deformilasa
IL173929A0 (en) Analogues of kahalalide f and pharmaceutical compositions containing the same
DE60333196D1 (de) Atemerfrischer und mundpflegeprodukt unter verwendung von kardamom l
EP1642969A4 (de) Fluoreszenzprotein und pigmentprotein
TW200510276A (en) Calcilytic compounds
DE602004002532D1 (de) Vorrichtung zur Herstellung von Broschüren
ATE548037T1 (de) Peptid-deformylase-hemmer
AU2002258437A1 (en) Peptide deformylase inhibitors
IS7441A (is) Peptíðdeformýlasatálmar
DE60232650D1 (de) Peptiddeformylaseinhibitoren
ATE531690T1 (de) Inhibitoren von peptiddeformylase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties